文献速递糖尿病

维生素D状态、维生素D受体基因多态性与2型糖尿病患者微血管并发症风险的前瞻性研究

Vitamin D Status, Vitamin D Receptor Polymorphisms, and Risk of Microvascular Complications Among Individuals With Type 2 Diabetes: A Prospective Study.
PubMed 文献 · Diabetes Care · 2023-01-01

该前瞻性研究纳入英国生物银行14,709例无微血管并发症的2型糖尿病患者,中位随访11.2年,发现血清25(OH)D水平较高与糖尿病微血管并发症(包括视网膜病变、肾病和神经病变)风险降低显著相关,且VDR基因多态性与25(OH)D存在联合关联但无显著交互作用。

要点

  • 与25(OH)D<25 nmol/L者相比,≥75 nmol/L者复合微血管并发症风险降低(HR 0.65,95%CI 0.51-0.84)。
  • 25(OH)D≥75 nmol/L者糖尿病视网膜病变、肾病、神经病变风险均显著降低。
  • VDR多态性与25(OH)D联合分析显示复合并发症风险降低,但无显著交互作用。

核心结论

  • 较高的血清25(OH)D浓度与糖尿病微血管并发症(包括视网膜病变、肾病和神经病变)风险降低显著相关。
  • 研究结果提示维持充足的维生素D状态可能在预防糖尿病微血管并发症中具有潜在益处。

研究设计与样本

  • 前瞻性研究,纳入英国生物银行14,709例无微血管并发症的2型糖尿病患者。
  • 通过电子健康记录确认糖尿病微血管并发症的发生,采用Cox比例风险回归模型估计风险比(HR)和95%CI。

主要发现

  • 血清25(OH)D中位浓度为40.7 nmol/L(四分位距27.5-56.4)。
  • 中位随访11.2年期间,1,370人发生糖尿病微血管并发症。
  • 与25(OH)D<25 nmol/L者相比,25(OH)D≥75 nmol/L者复合微血管并发症的多变量校正HR为0.65(95%CI 0.51-0.84)。
  • 与25(OH)D<25 nmol/L者相比,25(OH)D≥75 nmol/L者视网膜病变HR为0.62(95%CI 0.40-0.95),肾病HR为0.56(95%CI 0.40-0.79),神经病变HR为0.48(95%CI 0.26-0.89)。
  • 与25(OH)D<25 nmol/L且为次要等位基因纯合子(rs1544410的TT和rs731236的GG)者相比,25(OH)D≥50 nmol/L且为主要等位基因纯合子(CC和AA)者的复合微血管并发症多变量校正HR分别为0.54(95%CI 0.38-0.78)和0.55(95%CI 0.38-0.80),但未观察到显著交互作用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Evidence is limited regarding the associations between vitamin D status and microvascular complications in individuals with type 2 diabetes (T2D), among whom vitamin D deficiency or insufficiency is particularly common. In this study we aimed to prospectively investigate the associations of serum 25-hydroxyvitamin D [25(OH)D] and vitamin D receptor (VDR) polymorphisms with risk of diabetic microvascular complications. RESEARCH DESIGN AND METHODS: This analysis included 14,709 participants with T2D who were free of microvascular complications from the UK Biobank. Incidence of diabetic microvascular complications was ascertained via electronic health records. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% CIs. RESULTS: Median serum 25(OH)D concentration was 40.7 nmol/L (interquartile range 27.5, 56.4). During a median of 11.2 years of follow-up, 1,370 people developed diabetic microvascular complications. Compared with participants with 25(OH)D <25 nmol/L, individuals with 25(OH)D ≥75 nmol/L had a multivariable-adjusted HR of 0.65 (95% CI 0.51, 0.84) for composite diabetic microvascular complications, 0.62 (0.40, 0.95) for diabetic retinopathy, 0.56 (0.40, 0.79) for diabetic nephropathy, and 0.48 (0.26, 0.89) for diabetic neuropathy. In addition, in comparisons with participants with 25(OH)D <25 nmol/L and minor allele homozygotes (TT of rs1544410 and GG of rs731236), the multivariable-adjusted HRs of composite diabetic microvascular complications were 0.54 (0.38, 0.78) and 0.55 (0.38, 0.80) for participants with serum 25(OH)D ≥50 nmol/L and major allele homozygotes (CC and AA), respectively, although no significant interaction was observed. CONCLUSIONS: Higher serum 25(OH)D concentrations were significantly associated with lower risk of diabetic microvascular complications, including diabetic retinopathy, diabetic nephropathy, and diabetic neuropathy. Our findings suggest a potential beneficial role of maintaining adequate vitamin D status in the prevention of diabetic microvascular complications.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Chen X, Wan Z, Geng T, et al. Vitamin D Status, Vitamin D Receptor Polymorphisms, and Risk of Microvascular Complications Among Individuals With Type 2 Diabetes: A Prospective Study. Diabetes Care. 2023. PMID: 36169213. doi:10.2337/dc22-0513

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。